Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 10 of 10 for “"entecavir"”.
-
Entecavir Therapy for Patients with Hepatitis B Virus-Related Decompensated Cirrhosis
… 투여12개월 후 각각 7.24 (±2.0), 9.68(±4.85)로 감소하였다. 결론: Entecavir는 비대상성 간경변 환자에서 안전하게 간기능을 호전시켰다. INR이 엔테카비어 치료 효과를 예측할 수 있는 인자로 관찰되었다.
-
Efficacy of Entecavir in Patients with Hepatitis B virus-Related Decompensated Liver Cirrhosis
"배경/목적: 엔테카비어는 강력한 항 바이러스 효과와 적은 내성 발생률로 만성 B형 간염 환자에서 치료제로 사용되고 있다. 엔테카비어는 비대상 간경변 환자들에게도 안전하게 사용될 수 있는 치료제로 추천되나, 비대상 간경변 환자에서 치료 효과에 대한 연구보고는 드물다. 이에 저자들은 B형 간염에 의한 비대상 간경변 환자를 대상으로 엔테카비어 치료 효과를 알아보고자 하였다. 연구대상 및 방법: 2006년 11월부터 2009년 9월까지 아주대학교 병원에 내원한 만성 B형 간염으로 인한 비대상 간경변 환자 중 6개월 이상 …
-
Changes in serum histologic surrogate markers and procollagen III N- terminal peptide as independent predictors of HBeAg loss in patients with chronic hepatitis B during entecavir therapy
… patients with chronic hepatitis B (CHB) during entecavir treatment. DESIGN AND METHODS: Sixty CHB patients who received entecavir for > 12 months were included. We assessed serum markers of liver fibrosis and/or inflammation at baseline and after 12 months of entecavir treatment RESULTS: The …
-
Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance.
"본 연구에서는 이전에 라미부딘 및 아데포비어 내성을 보였던 환자를 엔테카비어로 전환하여 치료하여 이후 발생된 바이러스 반응, 엔테카비어 내성 및 라미부딘과 아데포비어 내성변종의 발현을 관찰하였다. 대상 환자는 예전에 라미부딘 내성을 보였던 아데포비어 내성 환자 중에서 6개월 이상 엔테카비어를 복용한 40명의 환자를 대상으로 하였으며 이들 환자에서의 바이러스 반응 및 엔테카비어 내성을 모니터링하였다. 전체 10% 환자에서 24주 동안의 엔테카비어 치료로 HBV DNA가 50 (copies/mL) 이하가 되었으며 40명의 환자 중 …
-
Multidrug-Resistant Hepatitis B Virus Resulting From Sequential Monotherapy With Lamivudine, Adefovir, and Entecavir: Clonal Evolution During Lamivudine Plus Adefovir Therapy
… with lamivudine (LAM), adefovir (ADV), and entecavir (ETV) during LAM plus ADV salvage therapy. METHODS: Sera were obtained from 6 patients who had developed sequential resistance to LAM, ADV, and ETV before and during LAM plus ADV therapy. The HBV genomes from each patient were amplified, …
-
Mathematical and Numerical Investigation of Immune System Development and Function
… that combined RNA interference drug ARC-520 with entecavir have shown promising results in reducing hepatitis B s antigen titers. We develop pharmacokinetic-pharmacodynamic models describing the mechanistic interactions of the drugs, hepatitis B virus DNA, and virus proteins. We fit the model to …
-
Clinical Course of Partial Virological Responders
Studies about long-term entecavir (ETV) therapy for partial virological response (PVR) are lacking. This study aimed to assess the clinical course of PVR patients receiving ETV therapy and analyze the efficacy of tenofovir (TDF). We retrospectively evaluated 130 patients who showed a PVR to ETV. …
-
Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
… DNA leave 6months space in 45 patients. (25 with entecavir, 14 with lamivudine, 6 with adefovir.) All patients had followed up at least 1 year after stopping NUC therapy. Serum ALT, AST and HBV DNA levels were measured every 3 months. Clinical relapse was defined as HBV DNA>2,000 IU and ALT or AST …
-
To Stop or Not to Stop: Response After Nucleos(t)ide Analogue Withdrawal Among Patients With Chronic Hepatitis B
… disoproxil fumarate (TDF) compared with entecavir (ETV) however, virological relapse occurred earlier in the TDF-treated group and rates of clinical relapse were also relatively higher in this group. The fourth study showed that the risk of hepatic decompensation was higher among …